` CDX (Cardiex Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

CDX
vs
S&P/ASX 300

Over the past 12 months, CDX has underperformed S&P/ASX 300, delivering a return of -12% compared to the S&P/ASX 300's 5% growth.

Stocks Performance
CDX vs S&P/ASX 300

Loading

Performance Gap
CDX vs S&P/ASX 300

Loading
CDX
S&P/ASX 300
Difference

Performance By Year
CDX vs S&P/ASX 300

Loading
CDX
S&P/ASX 300
Add Stock

Competitors Performance
Cardiex Ltd vs Peers

S&P/ASX 300
CDX
ABT
ISRG
BSX
SYK
Add Stock

Cardiex Ltd
Glance View

Market Cap
21.5m AUD
Industry
Health Care

CardieX Ltd. is engaged in the designing, manufacturing, and marketing of medical devices for use in cardiovascular health management. The company is headquartered in Sydney, New South Wales. The company went IPO on 2005-11-09. The firm is focused on designing, manufacturing and marketing medical devices for use in cardiovascular health management. The company operates through its subsidiaries, including ATCOR and CONNEQT. The firm's ATCOR division provides medical devices for measuring arterial stiffness and central blood pressure waveforms based on its FDA-cleared and patented SphygmoCor technology. Under the ATCOR.X brand, the Company also develops and licenses its Arty platform consisting of physiological and health analytics for wearable devices. The firm's digital platform, ArtyNet, is a connected software as a service ecosystem providing physicians with a telehealth solution for remotely managing patients' health. CONNEQT develops and markets consumer wearable and home health devices focused on heart health and its patented fitness and wellness parameters.

CDX Intrinsic Value
Not Available
Back to Top